Purpose: Algorithms using information from electronic health records to identify adults with type 1 diabetes have not been well studied. Such algorithms would have applications in pharmacoepidemiology, drug safety research, clinical trials, surveillance, and quality improvement. Our main objectives were to determine the positive predictive value for identifying type 1 diabetes in adults using a published algorithm (developed by Klompas et al) and to compare it to a simple requirement that the majority of diabetes diagnosis codes be type 1.
| INTRODUCTION
While algorithms using information from electronic health records (EHRs) that can identify individuals with diabetes have been well studied, [1] [2] [3] [4] there has been little development of similar algorithms to distinguish adults with type 1 diabetes from adults with type 2 diabetes.
Such algorithms could be used in in pharmacoepidemiology, drug safety research, clinical trial recruitment, surveillance, and quality improvement. For example, while the prevalence and incidence of type 1 diabetes in children has been well established through the SEARCH for Diabetes in Youth study, 5, 6 the prevalence of type 1 diabetes in adults is largely based on data from the National Health and Nutrition Examination Survey and the National Health Interview Survey, which are based on current insulin use and age of diagnosis. 7 However, an insulin use and age-based definition misclassifies adults with late-onset type 1 diabetes and individuals with early-onset type 2 diabetes who are quickly started on insulin and cannot be applied in most studies involving EHR data, where the age of diagnosis is usually unknown for prevalent cases of diabetes (or, if known, is documented in an EHR location that is not readily extractable into an electronic database). As a result, a 2015 workshop sponsored by the NIH Diabetes Mellitus Interagency
Coordinating Committee identified the "development and testing of a computable phenotype to identify people with type 1 diabetes in the electronic medical records" as an important priority area. 8 graphics, outpatient pharmacy dispensing, laboratory tests and laboratory test results, and diagnosis and procedure codes from outpatient and inpatient health care encounters from their EHR and other clinical and administrative data system. 13 For this project, we used the published SUPREME-DM DataLink diabetes registry criteria for diabetes identification. were not included because these agents could be used for other conditions. Criteria ascertained during periods of pregnancy were excluded.
In this analysis, we included individuals identified with diabetes using the SUPREME-DM criteria who had at least 1 day of enrollment • Using a cohort of 66 690 adults with diabetes, we determined the positive predictive value (PPV) for identifying type 1 diabetes in adults using a published algorithm (developed by Klompas et al).
• Both the Klompas algorithm and the requirement that the majority of diabetes diagnosis codes be for type 1 diabetes performed very well, with positive predictive values of 94.5% and 96.4%, respectively.
• Data from EHRs can be used to accurately identify adults with type 1 diabetes. We also reviewed all charts (n = 26) of individuals who met the ICD-9 criterion and who did not meet any Klompas algorithm criteria.
The gold standard was based on chart review. We followed the same methods as Klompas to identify the "true" diabetes type. The following "rules" were applied sequentially: endocrinology provider diagnosis if available (type 1 or 2), never on insulin (type 2), C-peptide negative or diabetes autoantibodies present (type 1), currently on insulin but prior history of prolonged treatment with oral hypoglycemic alone (type 2), and nonendocrinologist provider diagnosis (type 1 or 2). 
| ICD-10 codes
The United States transitioned to ICD-10 codes on October 1, 2015.
To assess the performance of the Klompas algorithm updated to include ICD-10 codes, we identified a cohort of individuals with diabetes who had continuous enrollment for the 9 months before and 9 months after October 1, 2015. We then compared use of the ICD-9 codes in the 9 months before and after October 1, 2015. Type 1 diabetes codes were considered to be ICD-9 250.x1, ICD-9 250.x3, and ICD-10 E10.xx. Type 2 diabetes codes were considered to be ICD-9
250.x0, ICD-9 250.x2, and ICD-10 E11.xx. We also examined the use of ICD-10 codes for secondary types of diabetes (E08.xx = diabetes mellitus due to underlying condition; E09.xx = drug or chemicalinduced diabetes mellitus; E13.xx = other specified diabetes mellitus).
| Statistical methods
To obtain PPVs, we weighted the cases based on our sampling framework. For each sample, we considered that entire sample as the numerator. The denominator was the number of charts in that sample that were reviewed. We then performed a domain analysis (Proc Surveymeans) in SAS version 9.4 (SAS Institute Inc, Cary, North Carolina), which allowed us to take into account the sampling while also simultaneously performing multiple comparisons. Hispanic, and had a lower body mass index than the entire diabetes cohort ( Table 1 ). The subset of 220 charts included in the chart review had similar characteristics as the full type 1 diabetes cohorts.
The PPV for the Klompas algorithm criteria 1 to 4 overall was 94.5% (Table 2) . We examined the performance of the 4 Klompas criteria in a hierarchical manner ( increases the estimated prevalence of type 1 diabetes among adults above ICD-9 criteria-based prevalence estimates with little change in PPV (decrease from 96.4% to 94.5% or 95.1%, depending on the specific criteria met).
As shown in Table 4 , the conversion between the ICD-9 and ICD-10 codes was quite good. Among individuals with a majority of type 1 ICD-9 codes in the 9 months prior to the ICD-10 transition, 92.4% had a majority of type 1 ICD-10 codes in the 9 months after the transition, and only 2.5% had a majority of type 2 ICD-10 codes in the 9 months after the transition (5.1% had no diabetes codes in that 9-month period). Among individuals with a majority of type 2 ICD-9 codes in The Klompas algorithm is fulfilled if any of the following four criteria are met: 1) Over 50% of diabetes codes (ICD-9 250.x0, 250.x1, 250.x2, and ICD-9 250.x3) were type 1 codes (ICD-9 250.x1, 250.x3), AND no dispensing for a non-insulin antidiabetic drug (excluding metformin); 2) Over 50% of diabetes codes (ICD-9 250.x0, 250.x1, 250.x2, and ICD-9 250.x3) were type 1 codes (ICD-9 250.x1, 250.x3), AND a dispensing for glucagon; 3) Dispensing of urine acetone test strips; 4) Negative C-peptide result or positive diabetes autoantibody result.
b
The ICD-9 criterion is fulfilled if over 50% of diabetes codes (ICD-9 250.x0, 250.x1, 250.x2, and ICD-9 250.x3) are type 1 codes (ICD-9 250.x1, 250.x3).
the 9 months prior to the ICD-10 transition, only 1.1% had a majority of type 1 ICD-10 codes in the 9 months after the transition. Among individuals who met the Klompas algorithm criteria for type 1 diabetes prior to the ICD-10 transition, 85.9% had a majority of type 1 ICD-10 codes in the 9 months after the transition. Less than 1% (288 out of 36 861) had any secondary diabetes ICD-10 codes (E08, E09, and E13).
| DISCUSSION
We conducted an external validation study of a published algorithm to identify adults with type 1 diabetes using data elements commonly In setting where C-peptide and diabetes autoantibodies laboratory results values are available, we recommend using the Klompas algorithm without the urine test strips criterion to identify type 1 diabetes in adults:
1. Over 50% of diabetes codes (ICD-9 250.x0, 250.x1, 250.x2, 250.
x3, or ICD-10 E9.xx, E10.xx) were type 1 codes (ICD-9 250.x1, 250.x3, or ICD-10 E10.xx) AND no dispensing for a non-insulin antidiabetic drug (excluding metformin).
2. Over 50% of diabetes codes were type 1 codes (same codes as in #1) AND a dispensing for glucagon.
3. Negative C-peptide result or positive diabetes autoantibodies laboratory test result.
In conclusion, we have confirmed the external validity and usefulness of 3 of 4 criteria in a published algorithm for identifying type 1 diabetes in adults. Further, we have demonstrated the utility and performance of using only coded diagnoses for identifying type 1 diabetes in adults. Data from EHRs can be used to accurately identify adults with type 1 diabetes without the need for chart review. These criteria could be used to identify type 1 diabetes for purposes of cohort identification, confounder or covariate definition, or as an outcome in safety surveillance studies. They thus have important potential applications in pharmacoepidemiology, drug safety research, clinical trial recruitment, surveillance, and quality improvement.
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